Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP621471.RAs7c163lMkN1sGhx8Eguhfgt7_9sR-_nLDnnWyJ6pkOI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP621471.RAs7c163lMkN1sGhx8Eguhfgt7_9sR-_nLDnnWyJ6pkOI130_assertion type Assertion NP621471.RAs7c163lMkN1sGhx8Eguhfgt7_9sR-_nLDnnWyJ6pkOI130_head.
- NP621471.RAs7c163lMkN1sGhx8Eguhfgt7_9sR-_nLDnnWyJ6pkOI130_assertion description "[G-17 was more frequent in high-grade tumors (69.1% versus 16.7%, P = 0.032), invasive tumors (63.6% versus 14.3%, P < 0.001), and in patients with CIS (77.1% versus 29.0%, P < 0.001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621471.RAs7c163lMkN1sGhx8Eguhfgt7_9sR-_nLDnnWyJ6pkOI130_provenance.
- NP621471.RAs7c163lMkN1sGhx8Eguhfgt7_9sR-_nLDnnWyJ6pkOI130_assertion evidence source_evidence_literature NP621471.RAs7c163lMkN1sGhx8Eguhfgt7_9sR-_nLDnnWyJ6pkOI130_provenance.
- NP621471.RAs7c163lMkN1sGhx8Eguhfgt7_9sR-_nLDnnWyJ6pkOI130_assertion SIO_000772 15351620 NP621471.RAs7c163lMkN1sGhx8Eguhfgt7_9sR-_nLDnnWyJ6pkOI130_provenance.
- NP621471.RAs7c163lMkN1sGhx8Eguhfgt7_9sR-_nLDnnWyJ6pkOI130_assertion wasDerivedFrom befree-20140225 NP621471.RAs7c163lMkN1sGhx8Eguhfgt7_9sR-_nLDnnWyJ6pkOI130_provenance.
- NP621471.RAs7c163lMkN1sGhx8Eguhfgt7_9sR-_nLDnnWyJ6pkOI130_assertion wasGeneratedBy ECO_0000203 NP621471.RAs7c163lMkN1sGhx8Eguhfgt7_9sR-_nLDnnWyJ6pkOI130_provenance.